Zura Bio (ZURA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.19
- Surprise
- —
- Score today
- 4.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22 — benzinga, 2026-08-12
- Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20 — benzinga, 2026-08-12
- Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZURA Sell at 4.3/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: ZB Assets (tibulizumab, torudokimab, crebankitug)
- Concentration risk — Counterparty: Pfizer and Eli Lilly license agreements
- DATA_ISSUE: analyst_target_implausible (raw $18.00 vs price $4.61 — ratio 3.9×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.79
- Price target
- $6.92
- Stop
- $4.44
- Upside to target
- +44.5%
Risk check: RSI 25 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
ZURA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $472.4M
- P/E (fwd)
- -8.5
- 52-week range
- $1.88–$7.44
- Off 52-week high
- 35.6%
- RSI (14)
- 25
- Volume vs avg
- 0.71×
- Score today
- 4.3/10